Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion

Mai Sato(Kyoto University), Shuichi Ito(Yokohama City University), Masao Ogura(Hokkaido University Hospital), Kenji Ishikura(Kitasato University), Koichi Kamei(National Center For Child Health and Development)
Clinical and Experimental Nephrology
April 22, 2017
10.1007/s10157-017-1415-8
Cited by 30

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135